Navigation Links
Fatigue, a common side effect of breast cancer treatment, evaluated in novel patient study
Date:12/18/2013

LOS ANGELES (Dec. 18, 2013) Although the prevalence and impact of cancer-related fatigue has been well established, very little is known about its predictors, mechanisms for development, and persistence post-treatment. A new research study at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in partnership with UCLA, is aimed at identifying breast cancer patients most susceptible to post-treatment fatigue by measuring biological, behavioral and social risk factors.

"Understanding who is at risk for post-treatment fatigue, and why, is the first critical step in the development of personalized, targeted interventions for the treatment and prevention of breast cancer-related fatigue," said Arash Asher, MD, director of cancer rehabilitation and survivorship at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and the medical center's primary investigator on the study. "It is our hope to identify the biological and behavioral risk factors that contribute to a patient's overall risk for fatigue."

The research study aims to identify biological factors that may cause more severe fatigue in patients post-treatment. Among the biological markers studied, researchers will evaluate the role of inflammation as a key mechanism for cancer-related fatigue. Extensive research has shown a correlation between inflammatory markers in the blood and levels of fatigue among patients during and after breast cancer treatment.

The study also will examine psychological factors, including a history of depression and early-life stressors, that may increase risk for developing post-treatment fatigue in women with early-stage disease.

"By identifying women who are at risk for post-treatment fatigue, our multidisciplinary breast cancer team can work to develop targeted therapies to prevent or ameliorate this disabling symptom," said M. William Audeh, MD, MS, medical director of the Wasserman Breast Cancer Risk Reduction Program at the Samuel Oschin Comprehensive Cancer Institute breast cancer program. "By providing a deeper understanding of genetic and biological disease characteristics, as well as risk profiles, the study may also lead to highly personalized breast cancer treatments for each individual diagnosed."

Patients will be evaluated just after diagnosis and surgery and prior to the start of chemotherapy, radiation therapy and hormonal treatments. In this narrow window of time, patients will take part in physical and psychosocial evaluations that examine genetic, biological and psychosocial factors that may cause inflammation and worsen fatigue. Patients will be followed for 18 months after treatment completion and evaluated on a six-month basis.

This study, known as the RISE Study (Research on Inflammation, Stress and Energy Study), was created by principal investigator Julienne E. Bower, UCLA associate professor of Psychology and Psychiatry/Biobehavioral Sciences. The study is funded by the National Cancer Institute.


'/>"/>

Contact: Cara Martinez
cara.martinez@cshs.org
310-423-7798
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers improve medical units to reduce nursing fatigue, cut costs
2. Researchers discover common cell wall component in Chlamydia bacteria
3. Avoid Common Holiday Dangers with Safety Tips from ESA
4. From common colds to deadly lung diseases, 1 protein plays key role
5. REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials
6. Symple Surgical Inc. Completes Series A Common Stock Financing
7. American Society of Hematology releases list of commonly used tests and treatments to question as part of Choosing Wisely campaign
8. Comfort & Harmony™, Makers of the mombo™ Nursing Pillow, Address Common Concerns for Moms New to Breastfeeding
9. Atlantic NeuroSurgical Specialists (ANS) Eradicates Common Misconceptions About Neurosurgery
10. Rare gene is common in african descendants and may contribute to risk of heart disease
11. New Guidance Limits Antibiotics for Common Infections in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
Breaking Medicine Technology: